Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

AGIO - Agios Pharmaceuticals, Inc. Latest News | Finranks

Home

AGIO

(AGIO)

NMS – Real Time Price. Currency in USD

29.43

-0.52 (-1.74%)

At close: Mar 27, 2026, 4:00 PM EDT

29.08

-0.35 (-1.19%)

After-hours: Mar 27, 2026, 5:45 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.: Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Agios Pharmaceuticals, Inc. investors. If you incurred a loss on your AGIO investment, please contact us using the link below to discuss your rights.

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.: Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Agios Pharmaceuticals, Inc. investors. If you incurred a loss on your AGIO investment, please contact us using the link below to discuss your rights.

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO

NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

Videos

No Data

There is no data to display

Press releases

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.: Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Agios Pharmaceuticals, Inc. investors. If you incurred a loss on your AGIO investment, please contact us using the link below to discuss your rights.

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.